March, of CEO to of Good and progress this am to thank COVID and our Director to opportunity safe, everyone have that going and you us. strategy are you this for share Thanks, joining proud hope Medical Jody. pandemic. end our the staying and your I'm afternoon families as and through I healthy joined Board as navigate I forward. you Ra excited at have and
Health more Joan legal among medical welcome and April I'd Joan life industry Before regulatory, to of and and XX Cardinal in Stafslien Board companies. brings getting as started, executive served like at joined than Directors. Nuvasive, Board experience to other science device having Medical the our of CareFusion years an to Ra
welcome So, Joan.
my many industry, large for we opportunities. looking years competitors. of as operating lead are differentiated and device experience capitalize officer manufacturing My executive the to Medical relatively the Medical, an and many the serve, includes forward versus those the and markets vascular two that ahead on space I'm Ra compelling at exciting our There challenges to pathways in focused Ra atherectomy. established of low the experience on serving attracted through in medical me companies including and leveraging reasons to reimbursement join cost of technology, growing
I backed was a I company served Corporation. for that with Operating Chief a medical First, X Executive for Atheromed, Spectranetics, was later peripheral venture products Chief coronary publicly Officer disease at treating traded Phillips in atherectomy Volcano that XXXX Officer was and President as later peripheral laser-based over at atherectomy also a company device capital and acquired by arterial billion. acquired
be it. Like to we were we by but for proactive many companies, have been preparing the COVID-XX and pandemic, in continued affected
the Our products guiding we distribute that to ensuring our limbs. and save customers business while and has employees been as of and lives manufacture protect principle health safety and continuity,
grateful community all masks first and are responders We able and are hospitals disposable April. our thankful local in workers have been XX,XXX in to to to healthcare to donate
sure Ra Medical the well as I'd the past has transformation undergone the to changes like make everyone and understands a quite few past during as forward. XX-months,
vascular start let's the First, business. with
Given related We force commercial disclosed, versus DABRA. the downsize a of a XX currently made year challenges the operations to to its decision five the have DABRA various significantly sales Company product ago. previously specialists appropriate clinical
We group sites customers well participate our may are atherectomy supporting with as significantly those the smaller who of focus study. core now a in being
XXXX. given slow progress a atherectomy enrolled initiated been first in challenge late XXXX. posing indication significant clinical are the has enrollment to been patient obtain the that most We with procedures elective from study February in COVID-XX patient FDA was a study Company for Since that canceled an to have The DABRA enrolled, postponed.
are to additional in start study. We clinical enrolling several the are participate and recently with engaging candidates second a sites that to cleared site patients
approval speed we the clinical trial. limitations the COVID-XX to up The to both reminder, impact sites have study. in to capital and continue a of include the XX for As may enrollment pandemic the
We clearer impacts call. to next have of these expect our a earnings by picture
we On identified front, DABRA underway limitations. have multiple the R&D efforts address to
through products is one number engineering for longer developed experience continuing a of work life time this perform This is ensure is First, catheters the we exploring calibration from team analysis the the not platform. issues The future of potential the extension project our to causes to as consistently the multiple team. have and prioritized of over all an and to the shelf will DABRA past. solutions essential the
seen to other use facilitate we will torque started We treatment allow braided number cases. to catheter jacket above the knee the More French a have and we've to to platform penetrate of her rapid These allow us larger over commonly a a larger efforts allow also the the issues initiated that vessels transmission of and kinking past DABRA guidewire and better better to of include engineering X a with recently, choice. had in atherectomy market. projects physicians pushability exchange exploring in were resist
year of of as excimer beginning have now product We believe design these We consistent in well have you engineering manner. as I'll of look and the the program efforts catheter arriving, a updating have management. quality further increased to laser development an team with products forward place in calls. the and in I with future since we Since professionals. capable team and engineering resources improvements delivering team on quality substantially areas various acumen the the consulting on
only in procedures. we that cases to other Most offices turning COVID-XX. to life performing starting threatening central March physician elective the business, a related on or note dermatology Before in stopped reduction and to saw like would I focused vascular cases
and cases instances translates to in performed Rutherford that in into prevent severe us, the amputations. order For above continuing be X more to many
have physician few like cases, offices of number words we to by business, practices a dermatology elective most relative dermatology involve need Now the COVID-XX. impacted been that like most a sizable significantly
replacements laser we do a sales. As are result, seeing reduction Pharos and a in
Looking from we forward, moved past DABRA on the COVID-XX, business Company, as significant as The focused to opportunity bringing a business. our the attention I think compelling grow we Pharos received technology market. commercial to not has we've have
a dermatology focus the and select to Our in capital further opportunity markets. the revenue and evaluate grow will efficient the quarter to U.S. be in business U.S. strategy develop next
to and this have plan intends quality remedy Another in Medical has comprehensive second procedures. on on amount identified improvement to the plan quality ago and months now weaknesses resources and The the big product later and assurance. XX a initiated this of weaknesses Company difference In all the the identify half made in of progress focus quality Company allocated year. XXXX, steady Ra intense is addressed processes versus to
previously disclosed, inspection site received for-cause Company a December, closed issued I of a an the Establishment in Inspection from following as observations audit. As three capital Form environment pleased possible. Report note, the was with and to to are be current or XXX of in am aware the as the XXXX. FDA Please FDA that very economic the XXXX February we need efficient EIR which note the
reduced well have XXXX level going reduction a procedures in began overall count While in of Note savings implementing our as the including we physician in key size we initiatives reduction beginning with continued spending the year invest we to performed of our cost offices right being adjust the continue initiatives, before head order to to strategic forward. Company. this of by the uncertainty as at that, to XX%, in initiatives QX
quality expenses have R&D focused and by have on retrenched initiatives. and reduced approximately In XX key commercially over product past the been fact, SG&A projects months, we XX% as
audit to with last comment of due but and to I area we has and isn't Before fees. turning cooperating can't uncovered facing nature we the will the the increased investigations the us. that the Andrew, call believe with during of legal year. substantially to Company appropriate to investigation that strategy is spend are unfortunate say investigations note legal ongoing one committee I that, various months our past over than I issues issues other the the the as navigate XX has that over deal This necessary
Now to financial the to I discuss our over Andrew turn results. call will Andrew?
